All In Biotech

Drug Trial Radar · NCT06052059

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,109 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,109

Actual

Start

Oct 25, 2023

Primary completion

Aug 12, 2026

Study completion Aug 1, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
PPD, Part of Thermo Fisher Scientific
First posted
Sep 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12.

Conditions

  • Ulcerative Colitis

Interventions

  • IV TulisokibartDrug

    Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously

  • IV PlaceboDrug

    Placebo matching IV tulisokibart

  • SC TulisokibartDrug

    Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously

  • SC PlaceboDrug

    Placebo matching SC tulisokibart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study 1: Percentage of Participants Achieving Clinical Remission Per Modified Mayo Score (MMS) at Week 12Time frame: Week 12
  2. Study 1: Percentage of Participants Achieving Clinical Remission Per MMS at Week 52Time frame: Week 52
  3. Study 2: Percentage of Participants Achieving Clinical Remission Per MMS at Week 12Time frame: Week 12

Locations

476 sites in 45 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists ( Site 0135)

    Dothan, Alabama

  • IMC-Gulf Coast Gastroenterology ( Site 0157)

    Fairhope, Alabama

  • Research Solutions of Arizona ( Site 3816)

    Litchfield Park, Arizona

  • One of a Kind Clinical Research Center ( Site 3852)

    Scottsdale, Arizona

  • GI Alliance - Sun City ( Site 0103)

    Sun City, Arizona

  • Clinnova Research ( Site 3803)

    Anaheim, California

  • Southern California Research Center ( Site 3828)

    Coronado, California

  • UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0113)

    La Jolla, California

  • Cedars-Sinai Medical Center ( Site 0119)

    Los Angeles, California

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3851)

    Orange, California

  • University of Colorado Anschutz Medical Campus-Division of Gastroenterology and Hepatology ( Site 0172)

    Aurora, Colorado

  • Peak Gastroenterology Associates ( Site 0116)

    Colorado Springs, Colorado

  • South Denver Gastroenterology, PC ( Site 3849)

    Englewood, Colorado

  • Rocky Mountain Gastroenterology/Topography Health ( Site 3838)

    Littleton, Colorado

  • Connecticut Clinical Research Institute ( Site 0126)

    Bristol, Connecticut

  • Medical Research Center of Connecticut ( Site 0151)

    Hamden, Connecticut

  • Yale University School of Medicine-Digestive Disease ( Site 0163)

    New Haven, Connecticut

  • Emerson Clinical Research Institute ( Site 3820)

    Washington D.C., District of Columbia

  • Gastroenterology Consultants of Clearwater ( Site 0152)

    Clearwater, Florida

  • University of Florida College of Medicine-Gastroenterology ( Site 3821)

    Gainesville, Florida

  • Nature Coast Clinical Research - Inverness ( Site 3806)

    Inverness, Florida

  • Central Florida Gastro Research ( Site 0124)

    Kissimmee, Florida

  • Research Associates of South Florida - Miami - Southwest 8th Street ( Site 3810)

    Miami, Florida

  • Orlando Health ( Site 0145)

    Orlando, Florida

  • USF Health ( Site 0169)

    Tampa, Florida

  • Emory University School of Medicine ( Site 3818)

    Atlanta, Georgia

  • Atlanta Gastroenterology Associates - Peachtree Dunwoody ( Site 0115)

    Atlanta, Georgia

  • Atlanta Center for Gastroenterology ( Site 0155)

    Decatur, Georgia

  • University of Chicago Medical Center ( Site 0134)

    Chicago, Illinois

  • GI Alliance - Glenview ( Site 0168)

    Glenview, Illinois

  • GI ALLIANCE - GURNEE ( Site 0107)

    Gurnee, Illinois

  • Iowa Digestive Disease Center ( Site 0123)

    Clive, Iowa

  • University of Louisville Hospital-Clinical Trials Unit ( Site 0165)

    Louisville, Kentucky

  • Baton Rouge General Medical Center - Bluebonnet ( Site 0112)

    Baton Rouge, Louisiana

  • Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 0154)

    New Orleans, Louisiana

  • Walter Reed National Military Medical Center ( Site 0121)

    Bethesda, Maryland

  • Woodholme Gastroenterology Associates-Woodholme Gastroenterology Associates ( Site 3835)

    Glen Burnie, Maryland

  • Massachusetts General Hospital-Crohn's and Colitis Center ( Site 0132)

    Boston, Massachusetts

  • University of Michigan ( Site 0143)

    Ann Arbor, Michigan

  • Clinical Research Institute of Michigan, LLC ( Site 0108)

    Clinton Township, Michigan

Showing 40 of 476 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.